New Agents Promote Neuroprotection in Parkinson's Disease Models

E-ISSN： 1996-3181|11|4|410-418

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.11, Iss.4, 2012-06, pp. : 410-418

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuroprotection for Parkinson’s disease: a new approach for a new millennium

By Drukarch Benjamin van Muiswinkel Freek L

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 10, 2001-10 ,pp. : 1855-1868

Informa Healthcare

Access to resources Recommend Favorite

Mitochondria: Prospective Targets for Neuroprotection in Parkinson’s Disease

Current Pharmaceutical Design, Vol. 20, Iss. 35, 2014-10 ,pp. : 5558-5573

Bentham Science Publishers

Access to resources Recommend Favorite

Adenosine A 2A receptor antagonists as new agents for the treatment of Parkinson's disease

By Richardson P.J. Kase H. Jenner P.G.

Trends in Pharmacological Sciences, Vol. 18, Iss. 9, 1997-10 ,pp. : 338-344

Elsevier

Access to resources Recommend Favorite

Tobacco Leaf, Smoke and Smoking, MAO Inhibitors, Parkinson's Disease and Neuroprotection; Are There Links?

By Castagnoli K. Murugesan T.

Neurotoxicology, Vol. 25, Iss. 1, 2004-01 ,pp. : 279-291

Elsevier

Access to resources Recommend Favorite

Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease

Current Pharmaceutical Design, Vol. 23, Iss. 33, 2018-01 ,pp. : 4936-4947

Bentham Science Publishers

Access to resources Recommend Favorite